Ligand acquires Ab Initio Biotherapeutics, an antigen-discovery company

Ligand acquires Ab Initio Biotherapeutics, an antigen-discovery company

Submitted by admin on July 24, 2019 - 10:20am
Source: 
Pharmaceutical Business Review
News Tags: 
Ligand Pharmaceuticals
Ab Initio Biotherapeutics
M&A
Headline: 
Ligand acquires Ab Initio Biotherapeutics, an antigen-discovery company
snippet: 

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash.

Do Not Allow Advertisers to Use My Personal information